We’ll be attending the “Nitrosamines Impurities Forum (Americas)” next week. Will you join us?

The CPhI Conferences event takes place August 26th-27th and aims to help the industry better understand the global regulatory and toxicological limits to combat nitrosamine impurities, including looking at the strategies used to identify these impurities at the right stage.

Pavel Pihera from the QUINTA-ANALYTICA team will be on-hand to offer expert advice, explain the science behind the detection methods used in Quinta, or just to say hello throughout the two days as the speeches and Q&A sessions evaluate the key analytical techniques used to identify these impurities, and study how adopting correct methodologies can help to avoid product recalls.

Be sure to swing into the chat zone and connect with Pavel if you’re attending, or visit Quinta.cz to learn more about nitrosamine impurities and how Quinta’s world-class detection techniques can help you navigate the sartan saga!

Additional News

  • 20 November 2025

    Webinar: Streamlined Evidence Strategies for Biosimilars: Analytics, PK and Immunogenicity in focus

    On behalf of Conscio Group, we are pleased to invite you to the upcoming free educational webinar from biosimilar series.

  • 11 September 2025

    Meet us at CPHI 2025

    This October, the global pharmaceutical community will gather in Frankfurt for CPHI 2025. Quinta-Analytica as a member of Conscio Group will be there too – visit us in the Contract Manufacturing Hall 5.1, Stand F1.

  • 8 September 2025

    Quinta-Analytica successfully passed two onsite FDA inspections

    In the first half of 2025, Quinta-Analytica underwent two onsite inspections by the U.S. Food and Drug Administration (FDA).